Similarly, high expression of METTL3 and IGF2BP1 can promote lenvatinib resistance in HCC cells, while high expression of RALYL enhances cisplatin and 5-fluorouracil resistance. This evidence concerns the gene METTL3 and hepatocellular carcinoma.